Talley 2000.

Methods	Randomised, double‐blind, placebo‐controlled trial. Multi‐centre (at least 2). Criteria for FD: equivalent symptom. with both types of FD
Participants	N = 609 Female: 69% Mean age: 46.3 years for the prokinetic group and 46.1 years for the placebo group Countries: USA and Europe
Interventions	Intervention: ABT‐229 1.25 mg, 2.5 mg, 5 mg and 10 mg twice a day Comparator: placebo Rescue medication: not mentioned Duration 4 weeks
Outcomes	Participant questionnaire, VAS 0‐100 used to assess severity, frequency and impact measured by 5‐graded Likert scale, duration one a 7‐graded Likert scale. Patient diary, severity of postprandial fullness, bloating, epigastric discomfort and postprandial nausea recorded on 7‐point Likert scale. Global evaluation at week 4 for excellent (complete or near complete resolution of symptoms), good (distinct improvement), moderate (some improvement), or poor (no change or deterioration). Assesed by participants.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "Randomized"
Allocation concealment (selection bias)	Unclear risk	No information
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double‐bledind. Placebo was identical to active therapy.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Assessed by patient who was blinded.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	8% (47/609) participants prematurely discontinued, the reasons were balanced between groups. The authors only reported outcome for 589 (96%) participants who had baseline data and at least one follow up assessment no more than 5 days and considered these participants as ITT population, which were 99%, 98%, 98% and 96% in active treatment but 95% in placebo group.
Selective reporting (reporting bias)	Low risk	Reported all pre‐defined outcomes
Other bias	Unclear risk	Difference in number baseline scores in table 1 and figure 2